Necrostatin-1

For research use only.

Catalog No.S8037

52 publications

Necrostatin-1 Chemical Structure

Molecular Weight(MW): 259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 130 In stock
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Necrostatin-1 has been cited by 52 publications

Purity & Quality Control

Choose Selective TNF-alpha Inhibitors

Biological Activity

Description Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
Features A powerful tool for characterizing the role of necroptosis with characterized primary target.
Targets
RIP1 [1]
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkXUOVDDqM7:TR?= MWOyOOKhcA>? NV3BS3dNcW6qaXLpeJMhVU2VLXnu[JVk\WRiY3XscEBl\WG2aB?= NXnQeVBlOjZ2N{K3NlM>
MEFs  NYHaWJQ3S2WubDDWbYFjcWyrdImgRZN{[Xl? Mn71NVDjiIoQvF2= MoPwOFghcA>? NVTScZlETE2VTx?= NU\ZNYZpcW6qaXLpeJMhgl[DRD3wdo9ud3SnZDDk[YF1cCCxZjDDUm9VOy2mZYDs[ZRm\CCPRV\z MYCyOlQ{Pzd6OR?=
BMDM  M4HHd2Z2dmO2aX;uJGF{e2G7 M3X3VVExyqEQvF2= NFXFfFY{OMLibXnu M2fDfpBzd3SnY4TzJINmdGy|IH\yc40hXEGNST3pcoR2[2WmIFzETEBz\WynYYPl NU\uU2ttOjZ|OEG2NFE>
NCI-H28 MmL5R4VtdCCYaXHibYxqfHliQYPzZZk> MXyxNOKh|ryP NHzDfWQzPMLiaB?= Mnr6dJJmfmWwdIOgSGFRTS2rbnT1Z4VlKHKnZIXjeIlwdiCxZjDOR2kuUDJ6IHPlcIwhfmmjYnnsbZR6yqB? MlLGNlYxODRzM{i=
MiaPaCa-2 NYiwSlZnTnWwY4Tpc44hSXO|YYm= MlLINlAh|ryP NH7ZOGEzPCCq M4LFbYRm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO= MXWyOlAxODZyNx?=
BxPC-3 MV\GeY5kfGmxbjDBd5NigQ>? NWLxRnV[OjBizszN MkPPNlQhcA>? NH24eVRl\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz M1XDVVI3ODByNkC3
SGC-7901 NEGwSZlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYLXN5FUOzEEoN88US=> M4P1WlHDqGh? MoTxd5VxeHKnc4Pld{BwgGGuaYDsZZRqdi2vZXTpZZRm\CClZXzsJIRm[XSq NYXrdZR{OjV5NkewO|Y>
KMS-12-PE  NHzLOJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXm2NEDPxE1? MV[1JIg> NF3pd|VqdmirYnn0d{BUUEtvaX7keYNm\CClZXzsJIRm[XSq MmfrNlU2OzByOUi=
L929-A  NVr2SXpSS2WubDDWbYFjcWyrdImgRZN{[Xl? NGC0bHg2OMLizszNxsA> MXmyOEBp M1XBVoJtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh? MnrGNlU{QTh3NEC=
L929-N  NXTvOmplS2WubDDWbYFjcWyrdImgRZN{[Xl? M3zRTFUxyqEQvF5CpC=> NY\M[ndQOjRiaB?= Ml3IZoxw[2u|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>? M3;xTFI2Ozl6NUSw
L929-A  MX;GeY5kfGmxbjDBd5NigQ>? MnnJOVDDqM7:TdMg MW[xNkBp NHPGbodjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= M4TYW|I2Ozl6NUSw
L929-N  NXTSSoNkTnWwY4Tpc44hSXO|YYm= MkXSOVDDqM7:TdMg NXXpdIZZOTJiaB?= NH[zb3JjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= MV2yOVM6QDV2MB?=
L929 NF\oXlZHfW6ldHnvckBCe3OjeR?= Mn;aOVDDqM7:TdMg NGrZ[48yOiCq NHq1PGVqdmirYnn0d{BVVkcQsT3pcoR2[2WmIFLp[EBkdGWjdnHn[S=> MVeyOVM6QDV2MB?=
L929-A NVTUZ2hOTnWwY4Tpc44hSXO|YYm= NUHEd|J[PTEEoN88UeKh NYK3fJVlOTJiaB?= MWHpcohq[mm2czD0bIUhXE6IzsGtbY5lfWOnZDDsc5N{KG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheGW{bXXhZoltcXS7 MXyyOVM6QDV2MB?=
L929 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXfme2ZrOzEEoN88US=> MlztNeKhcA>? M3u0R4lvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> MnHoNlUxQTV5NEK=
L929 M4HPbWNmdGxiVnnhZoltcXS7IFHzd4F6 NGnsRW0{OMLizszN NW[5WJFJOcLiaB?= NE\MbHRqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDjcIVifmGpZTDv[kBVd3CxIFm= MVqyOVA6PTd2Mh?=
Huh7 MnXNR4VtdCCYaXHibYxqfHliQYPzZZk> M3K5WFUxKML3TR?= MmHXNlQwPDhiaB?= MoD4SG1UVw>? NXvNdnNOeHKndnXueJMh[2WubDDk[YF1cCCxZjDyRYRJS1ZiY3:tbY5n\WO2ZXSgTJVpPyClZXzsdy=> NHnqOXgzPDl5M{K0NC=>
OHC M1fEdWZ2dmO2aX;uJGF{e2G7 NYDOe|RbOzBy4pEJ{txO NXPleJJITE2VTx?= MlTvbY5kemWjc3XzJI5wcXOnLXnu[JVk\WRiY3;u[IVve2WmIH71Z4xmcQ>? NFLLelczPDh5NEezOC=>
OHC M4nYbGZ2dmO2aX;uJGF{e2G7 NX7TV3U5OzBy4pEJ{txO NVnSWVc4TE2VTx?= MYjk[YNz\WG|ZYOgco9qe2VvaX7keYNm\CC|d3;scIVvKG63Y3zlbeKh Mme2NlQ5PzR5M{S=
OHC NX\vVnVMTnWwY4Tpc44hSXO|YYm= M1PBUVMxOOLCid88US=> M{[3Z2ROW09? MoKzdoV{fWy2czDpckBiKHKnZIXjeIlwdiCxZjDuc4l{\S2rbnT1Z4VlKFKLUEGgZY5lKFKLUEOgbY1ufW6xZnz1c5Jme2OnbnPl MnSwNlQ5PzR5M{S=
OHC M2nqVmZ2dmO2aX;uJGF{e2G7 MkXLN|Ax6oDLzszN Mo\6SG1UVw>? MWfkbY1qdmm|aHXzJI5wcXOnLXnu[JVk\WRiQV3QT{Bi[3SrdnH0bY9v NWL4clF[OjR6N{S3N|Q>
OHC MYHGeY5kfGmxbjDBd5NigQ>? NHz6NXQ{ODEkgJpOwG0> M2TOc2ROW09? M1H3VYlv[3KnYYPld{B1cGViboXtZoVzKG:oIHHwc5B1d3SrYzDPTGN{KHerdHjveZQh[Wy2ZYLpcochfGinIHzleoVteyCxZjDDR|gh[W[2ZYKgco9qe2ViZYjwc5N2emV? MVGyOFg4PDd|NB?=
SK-Hep1 Mn\vSpVv[3Srb36gRZN{[Xl? NIG2W4Q3OOLCid88UeKh M2LJNVE56oDLaB?= MmPFZoxw[2u|wrFOtk1t[XCjY3jvcoUucW6mdXPl[EBud3KyaH;sc4dq[2GuIHPoZY5o\SxiY3XscEBl\WG2aDDhcoQhWElidYD0ZYtm MWKyOFg{OjZyMh?=
SK-Hep1 NXzPe2JyTnWwY4Tpc44hSXO|YYm= MYm2NQKBkc7:TdMg NIewXmEyQOLCiXi= MmDybY5pcWKrdIOg{tIuVGGyYXPoc45mNWmwZIXj[YQhdGWja3Hn[UBw\iCKTVfCMVHDqA>? MV2yOFg{OjZyMh?=
SK-Hep1 NGTyRnVHfW6ldHnvckBCe3OjeR?= Moj2OlDjiIoQvF5CpC=> MoHmNVjjiImq M3nlPYJtd2Otc9Mg{tIudGGyYXPoc45mNW2nZHnheIVlKFCDUjDhZ4N2dXWuYYTpc44h[W6mIFHJSkB1emGwc3zvZ4F1cW:wIITvJJRp\SCleYTvd49tyqB? M{fLcVI1QDN{NkCy
L-540  NEHMWIZHfW6ldHnvckBCe3OjeR?= Ml3ROlDjiIoQvH2= NETvc2Uy6oDLaB?= MWLwdoV3\W62czD0bIUh\2WwZYLheIlwdiCxZjDSU3M> NXmxb25qOjR3NkG1NVk>
L-540  MmXQSpVv[3Srb36gRZN{[Xl? MYi2NQKBkc7:bR?= M3Pxc|HjiImq NV33PYZ7eHKndnXueJMhfGinIH3peI9kcG:wZILpZYwhdWWvYoLhcoUh\GWyb3zhdol7[XSrb36= NXf0N2FFOjR3NkG1NVk>
L-540  M2XnS2NmdGxiVnnhZoltcXS7IFHzd4F6 M37mb|Yx6oDLzszt MnPSNgKBkWh? NE\KOYVz\WS3Y3XzJJRp\SCJaY\pco9{fGG2L2PvdoFn\W6rYj3pcoR2[2WmIHPlcIwh\GWjdHi= M4fGNVI1PTZzNUG5
AGS MmPtR4VtdCCYaXHibYxqfHliQYPzZZk> MnvKOlDjiIoQvH2= NHrHXmwy6oDLaB?= NFvJ[HNxemW4ZX70d{B{cGmtb37pck1qdmS3Y3XkJINmdGxiZHXheIg> Mlr3NlQ1PjNzOUm=
NRK-52E  MlfkR4VtdCCYaXHibYxqfHliQYPzZZk> NIrMPJYzOCEQvF2= MXiyOEBp MVnwdo91\WO2czDj[YxteyCocn;tJINmdGxiZHXheIgh[2G3c3XkJIJ6KGm|Y3jlcYliKGmwaoXyfS=> NGDDZVEzPDN3MUi0OS=>
NRK-52E  MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2LWc|IxKM7:TR?= M2qzcVI1KGh? NYDmS2d[cW6lcnXhd4V{KGOnbHygeoli[mmuaYT5JIFnfGW{IGTOSk3PuSCVdHnteYxifGmxbjDhcoQhSVSSIFTldIxmfGmxbh?= MknENlQ{PTF6NEW=
NRK-52E  MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\ZUVIxKM7:TR?= NWq2UIJOOjRiaB?= Mmi0bY5pcWKrdIOgbY5kemWjc3XkJGRzeDFicILveIVqdiCneIDy[ZN{cW:wIHHmeIVzKFSQRj5OtUBUfGmvdXzheIlwdiCjbnSgRXRRKESncHzleIlwdg>? MmXBNlQ{PTF6NEW=
L929 NI\5RZZHfW6ldHnvckBCe3OjeR?= Ml[2Nk82yqEQvHevcYzDqA>? M3jjdVI1yqCq NVfCSmtVemW4ZYLz[YQhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ> MX2yN|k1OTd4OR?=
L929 M{XIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m1NVIwPcLizsznM41tyqB? M4nMblI1yqCq MlvjdoV3\XK|ZYOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZY5lKGOnbHyg[IVifGhiaX7keYNm\CCkeTDUUmbPuSCjbH;u[UBieyC5ZXzsJIF{KFSQRt8xxsAsyqC8VlHE M4T0RVI{QTRzN{[5
L929 NHe0T45HfW6ldHnvckBCe3OjeR?= MWiyxsDPxGdxbX|CpC=> NEXFZVgzPMLiaB?= NF7xZXJxem:vb4TzJINie3Cjc3WtOkApeDJyKTDhZ5Rqfmm2eTDhcoQheHKxY3HzdIF{\S14IHPs[YF3[Wen MVOyN|k1OTd4OR?=
L929 M1flb2Z2dmO2aX;uJGF{e2G7 NV25V2R4PcLizsznM41t M2\6[|I1yqCq M3rBZYJtd2OtczD6WmFFKGmwZIXj[YQhdmWlcn;weI9{cXNiYX7kJIF2fG:yaHHnfS=> MoHkNlM6PDF5Nkm=
C6 M4WwVmNmdGxiVnnhZoltcXS7IFHzd4F6 NX\HZYx6OSCvbX;sM2w> MkDjN{Bp NXHHTlRY[XS2ZX71ZZRmeyCVaHnrc45qdiCrbnT1Z4VlKGeuaX;tZUBk\WyuIHTlZZRp MlzaNlM5PDB2NEG=
U87 M2LZcWNmdGxiVnnhZoltcXS7IFHzd4F6 M4LER|EhdW2xbD;M MUKzJIg> M2XjXoF1fGWwdXH0[ZMhW2ira3;ubY4hcW6mdXPl[EBodGmxbXGgZ4VtdCCmZXH0bC=> MkSwNlM5PDB2NEG=
C6 NWDSem9{S3m2b4TvfIlkcXS7IFHzd4F6 M3HnSFEhdW2xbD;M NIrseY4{KGh? NXPPb29C[myxY3vzJJNpcWuxbnnuJIlv\HWlZXSgcoVkem:|aYO= NFy5NoIzOzh2MES0NS=>
U87 M4fITGN6fG:2b4jpZ4l1gSCDc4PhfS=> M2DXZlEhdW2xbD;M NV;vVYpJOyCq MYricI9kc3Nic3jpb49vcW5iaX7keYNm\CCwZXPyc5Nqew>? NYPQdmMxOjN6NEC0OFE>
C6 M3SyRWZ2dmO2aX;uJGF{e2G7 NUHuSmt3OSCvbX;sM2w> NHrYR|IyNjVvMzDo MmPWd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6= NF7PZVkzOzh2MES0NS=>
U87 MmXRSpVv[3Srb36gRZN{[Xl? MlfJNUBudW:uL1y= MkXlNU42NTNiaB?= NFqwR|h{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=> NYLjVHY{OjN6NEC0OFE>
TE671 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml;GOFDjiIoQvHevcYzDqA>? Mn;tNlQhcA>? NUfOd2ljemW|Y4Xld{BIYDF3LUC3NE1qdmS3Y3XkJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHl? M2fRb|I{PzR2Mkm2
RMS13 NXPNXIhrS2WubDDWbYFjcWyrdImgRZN{[Xl? MlXVOFDjiIoQvHevcYzDqA>? MUiyOEBp M161SZJme2O3ZYOgS3gyPS1yN{CtbY5lfWOnZDDsc5N{KG:oIHPlcIwhfmmjYnnsbZR6 NYntO3Q4OjN5NESyPVY>
MEFs NWXrNXZIS3m2b4TvfIlkcXS7IFHzd4F6 NVrzPFZxOi94L{KwJO69VQ>? MmPvNVghcA>? NGHneWJqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHigbY4hWmWuQTDLU{BOTU[| MlyzNlM4Ojd3OEG=
MEFs MmnnSpVv[3Srb36gRZN{[Xl? M2rzb|IxyqEQvF2= NY[xWFhCOS9{L{SgbC=> M1Xnc5N2eHC{ZYPz[ZMhXE6IzsGtbY5lfWOnZDDSTXBMOSCyaH;zdIhwenmuYYTpc44> MWKyN|czPzV6MR?=
ΔN-Karpas 299  NHG3WYJEgXSxdH;4bYNqfHliQYPzZZk> MmHzNlDDqM7:TR?= MVSxOkBp Mn2wbY5pcWKrdIOgR2Q{OC2rbnT1Z4VlKGOnbHyg[IVifGh? MlO5NlM2PDV7M{i=
MM.1S  MWLDfZRwfG:6aXPpeJkhSXO|YYm= MlnEPVAhyrWP M2\mRVEhcA>? NV7YS|BX[myxY3vzJGJCYSBzMT23NFgzKGmwZIXj[YQhemGyaXSgZ4VtdCC|d3XscIlv\w>? NIfk[|MzOzV{N{G1OC=>
KMS-12-BM M2GyPGN6fG:2b4jpZ4l1gSCDc4PhfS=> M{W1SFkxKML3TR?= M1HYV|EhcA>? MlPQZoxw[2u|IFLBXUAyOS15MEiyJIlv\HWlZXSgdoFxcWRiY3XscEB{f2WubHnu[y=> MkK3NlM2OjdzNUS=
HT-22  NXewZW0zS2WubDDWbYFjcWyrdImgRZN{[Xl? M3LkfFExyqEQvF2= M4\sTlEzyqCq MX;EUXNQ NVjxO|ZieHKxdHXjeJMh[WejaX7zeEBodHW2YX3heIUucW6mdXPl[EBk\WyuIHTlZZRp MUWyN|MxPzd3Mh?=
HT-22  NF;aSlJHfW6ldHnvckBCe3OjeR?= MXGyOeKh|ryP NWnzfXJ1OOLCk{OwxsBucW5? M4PtWWROW09? MY\pcohq[mm2czDFVmshSWO2aY\heIlwdiCrbnT1Z4VlKGK7IHfseZRidWG2ZR?= Mn33NlM{ODd5NUK=
NIH3T3  M2fBZWZ2dmO2aX;uJGF{e2G7 Mo\SNVAwPTBizszN NYX0c45OOS9|IHi= MkS5ZY1mdGmxcnH0[ZMhXE6IzsGt[JJqfmWwIHPvcZBt\XhiZn;ycYF1cW:w NUPUcZpCOjN{NkG2O|c>
SH-EP MkPpRZBweHSxc3nzJGF{e2G7 M4\sbVEx6oDLzszNxsA> NXjWeG57PzMkgJnoxsA> MYnpcohq[mm2czDJRXAhcW6qaXLpeI9zNSCjbnSgUIV5[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZM> MUCyNlg6ODN{Mh?=
HL60 MUPBdI9xfG:|aYOgRZN{[Xl? NFO5[HI3OCEQvF2= MVyxNkBp NWjjd4Fs\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MWeyNlg{PzZ6OR?=
HL60/Adr NUL2dVJpSXCxcITvd4l{KEG|c3H5 MVO2NEDPxE1? MmjDNVIhcA>? MmPP[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYO= M2fpTlIzQDN5Nki5
K562 MXfBdI9xfG:|aYOgRZN{[Xl? MVy2NEDPxE1? NVPSNlFqOTJiaB?= NVrKfIJC\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MVKyNlg{PzZ6OR?=
K562/Adr  NFf5fFlCeG:ydH;zbZMhSXO|YYm= Mn3XOlAh|ryP M4DpOFEzKGh? NHnCZ5RmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MYGyNlg{PzZ6OR?=
HL60 MnrYSpVv[3Srb36gRZN{[Xl? M{HLUlYxKM7:TR?= MWmxNkBp MWjheYdu\W62czD0bIUh[2G|cHHz[U0{KGGldHn2bZR6 MVSyNlg{PzZ6OR?=
HL60/Adr MlPlSpVv[3Srb36gRZN{[Xl? NH\td2I3OCEQvF2= MlPRNVIhcA>? MVzheYdu\W62czD0bIUh[2G|cHHz[U0{KGGldHn2bZR6 MoW0NlI5Ozd4OEm=
K562 M2CwUmZ2dmO2aX;uJGF{e2G7 Mn35OlAh|ryP NGjGSIwyOiCq NYrHfnlr[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= MX:yNlg{PzZ6OR?=
K562/Adr  M13wd2Z2dmO2aX;uJGF{e2G7 NUP4XpFxPjBizszN MVGxNkBp M4iwcYF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? Ml6yNlI5Ozd4OEm=
HL60 MYDGeY5kfGmxbjDBd5NigQ>? NF3GUVA3OCEQvF2= M{PJUlEzKGh? NISzbWhqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= NEjuPFczOjh|N{[4PS=>
HL60/Adr NFiyRW5HfW6ldHnvckBCe3OjeR?= MnzuOlAh|ryP M3zYR|EzKGh? NYXOTpRYcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 M2PBN|IzQDN5Nki5
K562 NXTmSFMzTnWwY4Tpc44hSXO|YYm= MnfNOlAh|ryP NEXJNmUyOiCq M1[0folv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= M1zrc|IzQDN5Nki5
K562/Adr  MWXGeY5kfGmxbjDBd5NigQ>? MWC2NEDPxE1? M2PwU|EzKGh? M{\6Zolv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= M2ThO|IzQDN5Nki5
L929sA M1vHTWFxd3C2b4Ppd{BCe3OjeR?= NFfrZWcyOCEQvF2= Moe5NUBp MmPobY5pcWKrdIOgeIhmKGGyb4D0c5Rq[yC{ZYPwc45{\SC2bzDUUmY> M3nWVlIzOzZ{N{[3
L929sA MWnBdI9xfG:|aYOgRZN{[Xl? MX6xNEDPxE1? Mn7xNUBp NV6xe3l5emW|Y4Xld{Bk\WyuczDlfJBz\XO|aX7nJHJKWEtzzqTJSEBnem:vIGTOSk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MmCyNlI{PjJ5Nke=
L929sA MVLBdI9xfG:|aYOgRZN{[Xl? M4fIPFExKM7:TR?= MXuxJIg> MmnPZYJzd2ejdHXzJJRp\SCrboTldoFkfGmxbjDv[kBk[XOyYYPlMVghf2m2aDDGRWRF M374cVIzOzZ{N{[3
TPC-1 NFjCcFdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVyxNFAh|ryP NX7pR253OjRiaB?= MU\EUXNQ M3TwdIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> Mne5NlIyOzZ6MUi=
8505c NVXyZ49GS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml7UNVAxKM7:TR?= M1HNVFI1KGh? M4rVfmROW09? MX3pcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= M3jrbFIzOTN4OEG4
SW13 NHzTTGdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml\UNVAxKM7:TR?= NFvqb|kzPCCq MULEUXNQ NWKy[IxwcW6lcnXhd4V{KGOnbHz1cIFzKHO3co\peoFt NEPaT2MzOjF|NkixPC=>
Jurkat  M3jxXGN6fG:2b4jpZ4l1gSCDc4PhfS=> NXKzbHNmPTBxIEGwNE8zODEEoN88cS=> MUGxM|MhcA>? NFW5b4Vz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? Ml24NlE2OzVyMkC=
Jurkat  MYTGeY5kfGmxbjDBd5NigQ>? M{PwRVIxOMLizszt MUmzNEBucW5? NV[5[IF[emWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBz\WGldHn2[UBwgHmpZX6gd5Bm[2mnczCoVm9UMSCpZX7ldoF1cW:w NH;pZ5MzOTV|NUCyNC=>
HT-22 M2mwW2N6fG:2b4jpZ4l1gSCDc4PhfS=> NGewV3IyOCEQvF2= MXuxNkBp NInYOo9xem:2ZXP0d{Bi\2GrboP0JINmdGxiZHXheIghcW6mdXPl[EBjgSB3wrDtcY9tN0xiZ3z1eIFu[XSnwrC= MWWxO|c3ODh4OR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

Protocol

Kinase Assay:

[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.33
Formula

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
Synonyms N/A
Smiles CN1C(=O)C(CC2=C[NH]C3=CC=CC=C23)NC1=S

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

TNF-alpha Signaling Pathway Map

Related TNF-alpha Products

Tags: buy Necrostatin-1 | Necrostatin-1 supplier | purchase Necrostatin-1 | Necrostatin-1 cost | Necrostatin-1 manufacturer | order Necrostatin-1 | Necrostatin-1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID